Glucan and Radiation
therapy and chemotherapy in the treatment of cancer often lead to
myelosuppression, a compromised ability to create new blood cells. In
this suppressed immune state, patients are more susceptible to
infections and other pathogenic challenges.
Research by the U.S. Armed Forces Radiobiology Research Institute and
others have found that systemic beta glucan reduces the time of recovery
from radiation-induced myelosuppression, synergizing with endogenous
cytokine and growth factor stimulation of hematopoeisis (formation of
blood cells) in the bone marrow. In a preclinical study, white blood
cell counts recovered 4 days faster than control animals following a
sublethal dose of radiation (Figure 1). The importance of this faster
recovery is evidenced by an increase in survival from 0% in control
animals to 50% in beta glucan treated animals following a lethal dose of
radiation (Figure 2).
Furthermore, beta glucan's unique mechanism action enhances the
microbial killing activities of the macrophages and neutrophils. This
important benefit provides the body with additional protection as it
struggles to restore its immune system defenses. There is significant
animal research demonstrating beta glucan's ability to enhance the
innate immune response against bacterial and viral infections, and also
demonstrating a synergistic effect when used in conjunction with
antibiotics (Figure 3).
Business Bureau listed Beta Glucan Wholesaler since 1994